ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer

被引：0
|
作者：
Subudhi, S. K. [1 ]
Wise, D. [2 ]
Liu, S. T. [3 ]
Chaudhry, A. [4 ]
Kim, J. [5 ]
Gardner, O. [6 ]
Gilbert, H. [6 ]
Grady, M. [6 ]
Paoloni, M. [6 ]
Krishnan, K. [6 ]
Carducci, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] NYU Langone Hlth, Med, New York, NY USA
[3] Univ Calif Los Angeles, Hematol Oncol, Los Angeles, CA USA
[4] Summit Canc Ctr, Med Oncol, Spokane, WA USA
[5] Yale Univ, Med Oncol, New Haven, CT USA
[6] Arcus Biosci, Clin Dept, Hayward, CA USA
[7] Johns Hopkins, Med Oncol, Baltimore, MD USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687TiP
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [1] A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer
    Wise, David R.
    Gardner, Olivia
    Gilbert, Houston N.
    Rieger, Aimee
    Paoloni, Melissa Constance
    Krishnan, Kartik
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Bendell, Johanna C.
    Carducci, Michael Anthony
    Kopp, Lisa M.
    Scott, Jennifer
    Grady, Michele M.
    Gardner, Olivia
    Wise, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
    Pook, David
    Geynisman, Daniel M.
    Carles, Joan
    de Braud, Filippo
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia L.
    Harris, Adam
    Huang, Kuan-Chieh
    Poon, Victor
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3292 - 3300
  • [4] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
    Rodriguez-Vida, A.
    Maroto Rey, J. P.
    Font Pous, A.
    Martin, C.
    Mellado, B.
    Corbera Lloret, A.
    Orrillo Sarmiento, M.
    Reig Torras, O.
    Querol Ninerola, R.
    Cano, L.
    Palazon, A.
    Alonso, J.
    Galtes, S.
    Juanpere, N.
    Juan, O.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S665 - S665
  • [5] A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Pook, David William
    Geynisman, Daniel M.
    Carles, Joan
    De Braud, Filippo G.
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal A.
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia
    Harris, Adam
    Huang, Kuan-Chieh
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Alejo Rodriguez-Vida
    Pablo Maroto
    Albert Font
    Cristina Martin
    Begoña Mellado
    Alex Corbera
    Mayra Orrillo
    Oscar Reig
    Rosa Querol
    Alejandro Rios-Hoyo
    Laia Cano
    Judith Alonso
    Gemma Martinez
    Susana Galtes
    Alvaro Taus
    Maria Martinez-Garcia
    Nuria Juanpere
    Oscar Juan
    Joaquim Bellmunt
    British Journal of Cancer, 2023, 128 : 21 - 29
  • [7] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Rodriguez-Vida, Alejo
    Maroto, Pablo
    Font, Albert
    Martin, Cristina
    Mellado, Begona
    Corbera, Alex
    Orrillo, Mayra
    Reig, Oscar
    Querol, Rosa
    Rios-Hoyo, Alejandro
    Cano, Laia
    Alonso, Judith
    Martinez, Gemma
    Galtes, Susana
    Taus, Alvaro
    Martinez-Garcia, Maria
    Juanpere, Nuria
    Juan, Oscar
    Bellmunt, Joaquim
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
  • [8] ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Krishnana, Kartik
    Giafis, Nick
    Scott, Jennifer
    Quah, Cheng Seok
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [9] A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
    Weber, J.
    Long, G. V.
    Haanen, J. B.
    Arance, A.
    Dummer, R.
    Nathan, P.
    Ribas, A.
    Ascierto, P. A.
    Robert, C.
    Gasal, E.
    D'Amelio, A., Jr.
    Bettinger, S.
    Boran, A. D.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)
    Robert, Caroline
    Dummer, Reinhard
    Arance, Ana
    Ribas, Antoni
    Weber, Jeffrey
    Long, Georgina V.
    Haanen, John
    Nathan, Paul
    Ascierto, Paolo A.
    Gasal, Eduard
    D'Amelio, Anthony
    Bettinger, Severine
    Boran, Aislyn D.
    Schadendorf, Dirk
    CANCER RESEARCH, 2019, 79 (13)
12345